INSP - Inspire Medical Systems, Inc.
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed.
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inspire Medical Systems, Inc. (NYSE: INSP). In August of 2025, contrary to the Company's repeated assurances that it had met all regulatory, technical, and commercial prerequisites for the launch of its Inspire V device, the Company disclosed that the launch faced an "elonga.
Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript
Inspire Medical's SLEEP 2026 updates spotlight new Inspire V data, remote patient tools and research supporting wider OSA therapy adoption.
Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research
MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026.
Alphatec bets on integrated spine surgery tech, while Inspire leads in sleep apnea devices with robust profitability. How do their financials and risks stack up?
Inspire Medical Systems faces a sharp revenue slowdown due to temporary CPT coding and CMS Project WISeR disruptions, not fundamental business weakness. INSP maintains a robust balance sheet with ~$400M in liquidity and zero debt, providing downside insulation and supporting a 1x EV/sales valuation at depressed prices. Competitive threats from Nyxoah and GLP-1 therapies are manageable, with IP litigation successes and GLP-1s potentially expanding INSP's addressable market.
Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
Inspire Medical Systems, Inc. (INSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Inspire Medical Systems, Inc. remains under pressure as Q1 revenue grew just 1.6% and management slashed 2026 guidance by up to 10%. INSP faces intensifying competition from GLP-1s and rival devices, reimbursement headwinds, and coding challenges with its new Inspire 5 system. Territory contraction and a shift to supporting existing accounts signal operational headwinds and a retreat from high-growth expansion.
INSP beats Q1 estimates but slashes 2026 outlook as reimbursement disruptions and WISeR program weigh on growth and procedure volumes.
Pre-Market Stock Futures: Futures are trading higher on Tuesday after new highs on Friday turned into a risk-off Monday, triggered by rising oil prices, a report that Iran attacked the UAE, and an additional report that the U.S. sank a boat in the Strait of Hormuz. All of the major indices finished the day lower,... Here Are Tuesday's Top Wall Street Analyst Research Calls: Applied Materials, Devon Energy, GoDaddy, Home Depot, Lam Research, Lowe's, Roblox, Tractor Supply, Ulta Beauty, and More
Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to earnings of $0.1 per share a year ago.
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2026.
MINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026. Inspire is scheduled to present at 11:00 a.m.
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.